169 related articles for article (PubMed ID: 7678041)
1. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.
Ibrahim GK; Kerns BJ; MacDonald JA; Ibrahim SN; Kinney RB; Humphrey PA; Robertson CN
J Urol; 1993 Jan; 149(1):170-3. PubMed ID: 7678041
[TBL] [Abstract][Full Text] [Related]
2. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues.
Robertson CN; Roberson KM; Herzberg AJ; Kerns BJ; Dodge RK; Paulson DF
Surg Oncol; 1994 Aug; 3(4):237-42. PubMed ID: 7530564
[TBL] [Abstract][Full Text] [Related]
3. Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.
Ibrahim GK; MacDonald JA; Kerns BJ; Ibrahim SN; Humphrey PA; Robertson CN
Surg Oncol; 1992 Apr; 1(2):151-5. PubMed ID: 1285216
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma.
Rana S; Sen R; Kalra R; Arora B; Sharma P; Gahlawat S
Indian J Pathol Microbiol; 2006 Oct; 49(4):495-9. PubMed ID: 17183836
[TBL] [Abstract][Full Text] [Related]
5. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.
Maygarden SJ; Strom S; Ware JL
Arch Pathol Lab Med; 1992 Mar; 116(3):269-73. PubMed ID: 1371380
[TBL] [Abstract][Full Text] [Related]
6. The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions.
Leav I; McNeal JE; Ziar J; Alroy J
Hum Pathol; 1998 Jul; 29(7):668-75. PubMed ID: 9670822
[TBL] [Abstract][Full Text] [Related]
7. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.
Häussler O; Epstein JI; Amin MB; Heitz PU; Hailemariam S
Hum Pathol; 1999 Sep; 30(9):1077-86. PubMed ID: 10492043
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue.
Turkeri LN; Sakr WA; Wykes SM; Grignon DJ; Pontes JE; Macoska JA
Prostate; 1994 Oct; 25(4):199-205. PubMed ID: 7521960
[TBL] [Abstract][Full Text] [Related]
10. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate.
Kirschenbaum A; Klausner AP; Lee R; Unger P; Yao S; Liu XH; Levine AC
Urology; 2000 Oct; 56(4):671-6. PubMed ID: 11018637
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma.
Işikay L; Yaman O ; Bozlu M; Müftüğlu YZ; Göğüş O
Int Urol Nephrol; 1995; 27(6):757-61. PubMed ID: 8725043
[TBL] [Abstract][Full Text] [Related]
13. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta expression in prostate neoplasia.
Cardillo MR; Petrangeli E; Perracchio L; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Feb; 22(1):1-10. PubMed ID: 10696454
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours.
Harper ME; Goddard L; Glynne-Jones E; Peeling WB; Griffiths K
Eur J Cancer; 1995; 31A(9):1492-7. PubMed ID: 7577078
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cytokeratin markers to differentiate between benign and malignant prostatic tissue.
Guinan P; Shaw M; Targonski P; Ray V; Rubenstein M
J Surg Oncol; 1989 Nov; 42(3):175-80. PubMed ID: 2478835
[TBL] [Abstract][Full Text] [Related]
17. Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis.
Petein M; Michel P; van Velthoven R; Pasteels JL; Brawer MK; Davis JR; Nagle RB; Kiss R
Am J Clin Pathol; 1991 Nov; 96(5):628-34. PubMed ID: 1719800
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
19. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
